OBJECTIVE:
To prove superior performance of the Ranger™ paclitaxel-coated PTA balloon catheter (Boston Scientific) for angioplasty of femoropopliteal artery lesions when compared to standard PTA balloons.

TRIAL DESIGN:
Prospective, multi-center, randomized controlled trial (3:1 Ranger DCB vs. standard PTA balloon). Follow up through 5 years.

RESULTS:

<table>
<thead>
<tr>
<th>OUTCOMES:</th>
<th>12-MONTH PRIMARY PATENCY RATES K-M ESTIMATE³</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Ranger</td>
<td>PTA</td>
</tr>
<tr>
<td>Primary Patency (%)</td>
<td>89.8%</td>
<td>74.0%</td>
</tr>
<tr>
<td>Months Since Index Procedure</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>At risk:*</td>
<td>n=278</td>
<td>n=98</td>
</tr>
</tbody>
</table>

0.0005

Log-rank**
P = 0.0005

*At risk denotes the number of subjects entered in the calculation at the time interval.

**Log-rank p-value compares the entire K-M curves from time zero to full one year follow-up window.

1. Core lab. 2. PACSS Grade 3/4 may be considered similar to moderate/severe calcification.

KEY BASELINE CHARACTERISTICS

<table>
<thead>
<tr>
<th>Age (year)</th>
<th>Smoker (current/previous)</th>
<th>Current Diabetes Mellitus</th>
<th>Target Lesion Length (mm)¹</th>
<th>Calcium: PACSS Grade 3/4²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ranger DCB (n=278)</td>
<td>70.6</td>
<td>85.3%</td>
<td>42.4%</td>
<td>82.5</td>
</tr>
<tr>
<td>PTA (n=98)</td>
<td>69.1</td>
<td>84.7%</td>
<td>43.9%</td>
<td>79.9</td>
</tr>
</tbody>
</table>

Presented by Marianne Brodmann, MD at LINC 2020
OUTCOMES ONE-YEAR FULL-COHORT RESULTS

CD-TLR & Mortality

Compared to PTA, Ranger demonstrated:

- Significantly lower TLR
- No difference in mortality

RANGER PK SUBSTUDY

Study Method:

- Protocol required blood draws: Baseline, 10 minutes, 30 minutes, 1, 3, 6, 24 or 48 hours, 7 days and 30 days after last Ranger DCB treatment and removal
- All 12 patients received Ranger DCB
- Average number of DCBs used per patient: 1.75

At 1 hour 11 of 12 patients did not have measurable levels of paclitaxel in the blood stream.

3. Kaplan-Meier Estimate: Primary patency as determined by duplex ultrasound (DUS) Peak Systolic Velocity Ratio (PSVR) is ≤ 2.4 at the 12-month follow-up visit, in the absence of clinically-driven TLR or bypass of the target lesion.
4. At risk denotes the number of subjects entered in the calculation at the time interval.
5. Log-rank p-value compares the entire K-M curves from time zero to full one year follow-up.
6. Measurable level is 1.0 ng/ml.
7. Paclitaxel in the blood stream was below measurable levels at 3 hours in all 12 patients.

CAUTION: Ranger is an Investigational Device. Limited by Federal for US law to investigational use only. Not available for sale. Ranger™ Paclitaxel Coated PTA Balloon Catheter is manufactured by Hemoteq AG. All cited trademarks are the property of their respective owners.